Drug Resistance in Tuberculosis
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 2604
Special Issue Editor
Interests: Mycobacterium tuberculosis; Mycobacteria; antibiotic resistance; persistence; virulence; diagnostics; vaccines; systems modeling; SARS-CoV-2 coinfection
Special Issue Information
Dear Colleagues
Even as the COVID-19 pandemic rages on, tuberculosis (TB) remains the deadliest human infection, claiming over 1.5 million lives annually, and one billion lives in the last 200 years—more than malaria, influenza, smallpox, HIV/AIDS, cholera, and plague combined. One of the main challenges in global TB control is the emergence of drug-resistant TB (DRTB). While the incidence of TB is declining, the incidence of DRTB is rising, with a prevalence well above 50% in some regions. This Special Issue focuses on genomic and epigenetic mechanisms, emergence, transmission, and virulence of DRTB. Of special interest is resistance to new and repurposed drugs for the treatment of MDR-TB (e.g., bedaquiline, delamanid, clofazimine, and linezolid), or regimens and drug candidates in clinical trials. Research that clarifies the role of persistence and tolerance in the emergence of DRTB, or modeling (e.g., metabolic, regulatory) that enlightens the processes and conditions that lead to the emergence of persistence and DRTB is also welcome. Finally, considering the current pandemic, research furthering our understanding of how COVID-19 infection affects the pathology and pathogenesis of DRTB, the preferred treatment course for TB, and the activation of TB is welcome.
For this Special Issue, I invite review or original research articles related to the topics above.
Prof. Dr. Faramarz Valafar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- resistance
- persistence
- evolution
- genomic
- epigenetic
